Pre-made Avdoralimab benchmark antibody ( Whole mAb, anti-C5AR1 therapeutic antibody, Anti-C5AR/C5R1/CD88 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Avdoralimab biosimilar, Whole mAb, Anti-C5AR1 Antibody: Anti-C5AR/C5R1/CD88 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Avdoralimab (IPH 5401, formerly NN 8210) is a complement C5a receptor antagonist (Anti-C5aR-215) recombinant human monoclonal antibody, being developed by Innate Pharma, for the treatment of solid tumours, chronic spontaneous urticaria [chronic urticaria in development table], Bullous-pemphigoid and COVID-19 pneumonia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-039-1mg	1mg	3090
GMP-Bios-ab-039-10mg	10mg	Inquiry
GMP-Bios-ab-039-100mg	100mg	Inquiry
GMP-Bios-ab-039-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Avdoralimab biosimilar, Whole mAb, Anti-C5AR1 Antibody: Anti-C5AR/C5R1/CD88 therapeutic antibody
INN Name	Avdoralimab
Target	C5AR1
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Novo Nordisk;Innate Pharma
Conditions Approved	na
Conditions Active	Bullous pemphigoid;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours
Conditions Discontinued	Rheumatoid arthritis
Development Tech	na